Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 11 of 115, showing 5 Applications out of 571 total, starting on record 51, ending on 55

# Protocol No Study Title Investigator(s) & Site(s)

51.

ECCT/25/04/03   PRETERM AFRICA STUDY
    Pragmatic Evaluation of Therapies to Enhance Respiratory Management in Preterm Infants in Africa   
Principal Investigator(s)
1. Nayirat Mohamed
Site(s) in Kenya
1. Coast General Teaching and Referral Hospital (Mombasa county)
 
View

52.

ECCT/25/04/02   PRETERM AFRICA STUDY
    Pragmatic Evaluation of Therapies to Enhance Respiratory Management in Preterm Infants in Africa   
Principal Investigator(s)
1. Justus Simba
Site(s) in Kenya
1. Mama Lucy Kibaki Hospital (Nairobi City county)
 
View

53.

ECCT/25/04/01   PHASE 2/3 OF SII-TCV(B)
    A PHASE 2/3, DOUBLE-BLIND, RANDOMIZED, ACTIVE CONTROLLED STUDY TO EVALUATE THE SAFETY, IMMUNOGENICITY AND IMMUNE NON-INTERFERENCE OF A BIVALENT CONJUGATE VACCINE AGAINST SALMONELLA ENTERICA SEROVARS TYPHI AND PARATYPHI A IN HEALTHY INFANTS AGED 9 TO 12 MONTHS   
Principal Investigator(s)
1. WALTER OTIENO
Site(s) in Kenya
VICTORIA BIOMEDICAL RESEARCH INSTITUTE
 
View

54.

ECCT/25/03/07   Sparkle - Site 1405
    A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises   
Principal Investigator(s)
1. Prof Videlis Nduba
Site(s) in Kenya
1. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county)
2. Ahero Clinical trials Unit (Kisumu county)
3. International Cancer institute (Uasin Gishu county)
4. Kondele Childrens Hospital (Kisumu county)
5. Gertrudes Children’s Hospital (Nairobi City county)
6. Victoria Biomedical Research Institute (Kisumu county)
 
View

55.

ECCT/25/03/06   Sparkle Study-Site 1404
    A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises   
Principal Investigator(s)
1. Godfrey Allan Otieno
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
2. Ahero Clinical trials Unit (Kisumu county)
3. International Cancer institute (Uasin Gishu county)
4. Kondele Childrens Hospital (Kisumu county)
5. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county)
6. Gertrudes Children’s Hospital (Nairobi City county)
 
View